Covid-19 and is already being used in clinical practice. The European Commission signed a 63 million-euro ($74 million) contract with Gilead this week for batches of the drug to be made available in European Union countries from early August.Remdesivir may be effective in reducing recovery time in patients with severe Covid-19, though more trials are needed to confirm this, the experts said.
The drug probably has no important effect on the need for mechanical ventilation and may have little or no effect on the length of hospital stay.Gilead said in June that it will charge U.S.
hospitals roughly $3,120 for a course of treatment of remdesivir for most patients. The drug received an emergency use authorization from U.S.